BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Harvard Mental Health Letter Reports On The Link Between Antidepressant Treatment And Increased Risk Of Suicide


10/19/2005 5:11:32 PM

BOSTON, May 27 /PRNewswire/ -- Depression is a serious illness that increases the risk of suicide. This March, the FDA issued a Public Health Advisory in response to a possible connection between the antidepressant paroxetine (Paxil) and thoughts of suicide or self-destructive behavior in some teens and children. The June issue of the Harvard Mental Health Letter discusses the FDA advisory and offers suggestions to people taking antidepressants.

The advisory targeted ten antidepressants in addition to Paxil and urged drug companies to add a prominent warning to their labels calling for close observation of anyone starting or changing the dose of an antidepressant. Although no suicides were reported in Britain where the connection between Paxil and suicide was first noted, the FDA decided to act conservatively while preparing to investigate the issue further.

According to the Harvard Mental Health Letter, if you're considering antidepressant medication, you should first be fully evaluated by your doctor. Also consult your doctor about all possible treatments for depression, including medications and psychotherapy.

If you already have an antidepressant treatment established, do not change a thing. Additionally, talk to your doctor before stopping your medications because you can develop uncomfortable discontinuation symptoms.

Dr. Michael Miller, the editor-in-chief of the Harvard Mental Health Letter, believes that if all patients and doctors heed recommendations from the FDA advisory, antidepressant treatment will be much safer. Dr. Miller also notes that this warning should not be interpreted as a reason to fear medication or reject them entirely. In many cases, the risks of depression are much greater than the risks of antidepressants.

The Harvard Mental Health Letter is available from Harvard Health Publications, the publishing division of the Harvard Medical School. You can subscribe to Harvard Mental Health Letter for $59 per year at http://www.health.harvard.edu/ or by calling 1-877-649-9457 toll-free.

Media: contact Christine Junge at Christine_Junge@hms.harvard.edu for a copy of the newsletter, or to receive our press releases directly.

About Harvard Health Publications

Harvard Health Publications, a division of Harvard Medical School, publishes five monthly newsletters as well as more than 50 special health reports and books. For more information visit our Web site, http://www.health.harvard.edu/.

Harvard Health Publications

CONTACT: Christine Junge of Harvard Health Publications,+1-617-432-4717, Christine_Junge@hms.harvard.edu



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES